Fig. 4: FORTIS can detect the activity of the cognitive enhancer FGL.

a Heat map of SEP-GluA1 fluorescence where each square represents a single hippocampal culture in a 96-well plate, measured following a 48 h exposure to different doses of FGL (10, 25, 50, 125, and 200 µg/ml). b Fluorescence intensity as a function of FGL dose. c Representative immunoblots show the levels of S831 phosphorylated GluA1 in dissociated neurons treated with different concentrations of FGL for 48 h. Actin was used as a loading control. d Quantification of pGluA1/tGluA1 following treatment with different concentrations of FGL. e Heat map of SEP-GluA1 fluorescence measured following a 48 h exposure to FGL (25 µg/ml) in combination with TTX (3 μM) or the PI3K inhibitor LY294002 (10 μM). f Fluorescence intensity as a function of FGL, TTX, and LY294002 treatment. N in b, d, and f represents the number of cultures. Statistical significance in b, d, and f was calculated according to the Mann–Whitney test followed by Tukey’s multiple comparisons post hoc tests, and the data are presented as the mean ± SEM. g, h Long-term monitoring of pHuji-GluA1 fluorescence following the administration of PD98059 (25 μM), chelerythrine (10 μM), KN93 (20 μM), or KN92 (20 μM). The p values were determined with two-way ANOVA.